leadf
logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy focuses on regulatory approval for LIGHT cancer treatment

Snapshot

The first cancer patient to be treated by LIGHT is slated for 2021

harley street

Quick facts: Advanced Oncotherapy PLC

Price: 30.5 GBX

LSE:AVO
Market: LSE
Market Cap: £93.44 m
Follow
  • Developing a smaller, more affordable proton beam therapy system called LIGHT

  • First patient set to be treated at Harley Street building next year

  • Technology-based on work by ADAM, a spin-off of CERN

 

What Advanced Oncotherapy does:

Advanced Oncotherapy PLC (LON:AVO) is developing a state-of-the-art, affordable proton beam therapy system called LIGHT.

The technology is based on work by ADAM, which AVO bought in 2013 from CERN – the particle physics lab that built the Hadron collider.

The major plus point of proton therapy is that it can pinpoint tumours more precisely, which means less damage to surrounding healthy tissues.

Proton therapy facilities have traditionally been pricey and large, requiring a space the size of a football pitch to run.

But AVO thinks it has solved that problem, and LIGHT is being built to fit in the basement of a townhouse in Harley Street, central London.

Its modular design, lighter weight and better proton efficiency also help to keep costs down, which should open proton therapy up to many more patients.

 

How it’s doing

In June, AVO announced a new strategic funding partnership and debt facility.

The funding, which totals roughly £42mln, will go towards the development of the LIGHT system and manufacturer of up to 30 LIGHT systems.

The company has entered into a €20mln unsecured loan agreement with VDL Participatie, a member of VDL Groep, an industrial family-owned group of companies that manufactures kit used in the Advanced Oncotherapy's LIGHT System.

It has also entered into an interest-bearing secured convertible facility with Nerano Pharma, a financing vehicle wholly owned by existing Advanced Oncotherapy shareholder Seamus Mulligan, for up to US$30mln.

In February, AVO said it had selected The London Clinic to staff and run a second proton beam facility.

The two companies have signed an outline deal called a memorandum of understanding under which AVO will lease part of The London Clinic's premises to install the treatment room.

A profit-sharing agreement has been put in place, although full commercial details were not revealed.

What the boss says: Nicholas Serandour, chief executive

"Because our LIGHT system has been designed to significantly reduce the treatment cost of patient and it can be installed in small to mid-size health care centres throughout the country, every patient ought to benefit from a proton therapy centre in their vicinity which is expected to drive patients’ demand for this treatment."

Inflexion points

  • Construction of the first centre in Harley Street is completed 
  • Treatment of the first patient in 2021
  • AVO predicts 9,000 additional treatment rooms will be needed by 2040

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17

3 min read